Skip to search formSkip to main contentSkip to account menu

AZD6482

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A NOVEL, INTEGRATED GENE EXPRESSION AND DRUG SENSITIVITY APPROACH REVEALS UNIQUE SENSITIVITY OF SQUAMOUS CELL CARCINOMA‐LIKE BLADDER CANCERS TO PI3K&bgr; INHIBITOR AZD6482: MP88‐18
2016
2016
Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer
Breast cancer is one of the leading causes of death for women worldwide. Among various subtypes of breast cancer, human epidermal… 
2015
2015
High selectivity of PI3Kβ inhibitors in SETD2-mutated renal clear cell carcinoma.
PURPOSE Clear cell renal cell carcinoma (ccRCC) is characterized with frequent mutations of SETD2 gene and our purpose was to… 
2014
2014
Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as oral PI3Kβ inhibitors, useful as antiplatelet agents.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)